Terms: = Lung cancer AND RPL22, EAP, 6146 AND Treatment
29 results:
1. Expanded Access Program Pralsetinib in Advanced Non-Small Cell lung cancer with Rearranged during Transfection (RET) Gene Rearrangement.
Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
[TBL] [Abstract] [Full Text] [Related]
2. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (eap).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract] [Full Text] [Related]
3. Bioinformatics Identification of Key Genes for the Development and Prognosis of lung Adenocarcinoma.
Luo X; Xu JG; Wang Z; Wang X; Zhu Q; Zhao J; Bian L
Inquiry; 2022; 59():469580221096259. PubMed ID: 35635202
[TBL] [Abstract] [Full Text] [Related]
4. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract] [Full Text] [Related]
5. Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme.
Chan OSH; Lee VHF; Nyaw SF; Kam MTY; Lee KWC; Lam KC
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e305-e314. PubMed ID: 33589348
[TBL] [Abstract] [Full Text] [Related]
6. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract] [Full Text] [Related]
7. Real-world data from the Portuguese Nivolumab Expanded Access Program (eap) in previously treated Non Small Cell lung cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract] [Full Text] [Related]
8. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Crinò L; Bronte G; Bidoli P; Cravero P; Minenza E; Cortesi E; Garassino MC; Proto C; Cappuzzo F; Grossi F; Tonini G; Sarobba MG; Pinotti G; Numico G; Samaritani R; Ciuffreda L; Frassoldati A; Bregni M; Santo A; Piantedosi F; Illiano A; De Marinis F; Tamberi S; Giannarelli D; Delmonte A
Lung Cancer; 2019 Mar; 129():35-40. PubMed ID: 30797489
[TBL] [Abstract] [Full Text] [Related]
9. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
[TBL] [Abstract] [Full Text] [Related]
10. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O; Vogelzang NJ; Sweeney C; Fernandez DC; Almeida F; Iagaru A; Brown A; Smith MR; Agrawal M; Dicker AP; Garcia JA; Lutzky J; Wong YN; Petrenciuc O; Gratt J; Shore ND; Morris MJ;
Oncologist; 2018 Feb; 23(2):193-202. PubMed ID: 29183960
[TBL] [Abstract] [Full Text] [Related]
11. Liver Metastasis and treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Tumeh PC; Hellmann MD; Hamid O; Tsai KK; Loo KL; Gubens MA; Rosenblum M; Harview CL; Taube JM; Handley N; Khurana N; Nosrati A; Krummel MF; Tucker A; Sosa EV; Sanchez PJ; Banayan N; Osorio JC; Nguyen-Kim DL; Chang J; Shintaku IP; Boasberg PD; Taylor EJ; Munster PN; Algazi AP; Chmielowski B; Dummer R; Grogan TR; Elashoff D; Hwang J; Goldinger SM; Garon EB; Pierce RH; Daud A
Cancer Immunol Res; 2017 May; 5(5):417-424. PubMed ID: 28411193
[TBL] [Abstract] [Full Text] [Related]
12. Mutation Profiling of lung cancers with Long-Term Response to Gefitinib Therapy.
Gautschi O; Stadelmann C; Aebersold-Keller F; König K; Büttner R; Heukamp LC; Betticher D; Baumann C; Buser K; Calderoni A; Casty A; DʼAddario G; Irlé C; Mamot C; Morant R; Trojan A; Pellicioli E; Jehle-Schwertfeger S; Aebi S; Diebold J
Oncol Res Treat; 2015; 38(11):560-9. PubMed ID: 26599269
[TBL] [Abstract] [Full Text] [Related]
13. [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
Li L; Zhong W; Liao M; Chen L; Han B; Guan Z; Yu S; Liu X; Wu Y; Jiang G; Xu J; Chen J; Tao M; Luo R; Li W; Xu N; Zhao X; Wang M
Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):332-9. PubMed ID: 22681919
[TBL] [Abstract] [Full Text] [Related]
14. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
[TBL] [Abstract] [Full Text] [Related]
15. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (eap)].
Huang H; Zhang Y; Zhao HY; Wang ZQ; Xu F; Xu GC; Zhang L; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):148-51. PubMed ID: 19538895
[TBL] [Abstract] [Full Text] [Related]
16. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract] [Full Text] [Related]
17. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
Govindan R; Natale R; Wade J; Herbst R; Krebs A; Reiling R; Hensing T; Wozniak A; Belani CP; Kelly K; Ochs J
Lung Cancer; 2006 Sep; 53(3):331-7. PubMed ID: 16797779
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme.
Ostoros G; Harisi R; Kovacs G; Horti J; Geczi L; Szondy K; Orosz M; Ferenczi E; Ruby E; Dome B
Anticancer Res; 2005; 25(6C):4759-62. PubMed ID: 16334173
[TBL] [Abstract] [Full Text] [Related]
20. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
[TBL] [Abstract] [Full Text] [Related]
[Next]
